View source for Reduced Nicotinamide Mononucleotide (NMNH)

Reduced Nicotinamide Mononucleotide (NMNH), discovered in 2021, represents a novel [[NAD+ Precursor|NAD+ precursor]], offering a promising alternative to the more commonly known compounds such as [[Nicotinamide Mononucleotide (NMN)]] and [[Nicotinamide Riboside (NR)]]. Unlike these precursors, NMNH exhibits a remarkable ability to elevate NAD+ levels in cells more effectively and at a faster rate in mice. NMNH operates via a novel metabolic pathway that is independent of the enzymes NRK (Nicotinamide Riboside Kinase) and NAMPT (Nicotinamide Phosphoribosyltransferase). This distinct mechanism not only sets NMNH apart from other NAD+ precursors but also contributes to its heightened efficacy in boosting NAD+ levels within cells. When administered to mice, NMNH has shown a rapid and sustained increase in NAD+ levels across a variety of tissues including the liver, kidney, muscle, brain, brown adipose tissue, and heart. Interestingly, this effect was not observed in white adipose tissue. This broad-spectrum increase in NAD+ levels underscores the potential of NMNH as a robust and efficient NAD+ precursor, offering new possibilities for its application in health and longevity research.{{pmid|33724555}} 

In 2022, first mass production of NMNH was reported by a Chinese biotech company <ref>https://www.bontac-bio.com/en/news-detail.aspx?id=12343&cid=51</ref>.

== References ==
<references />
[[Category:Orally Consumable Longevity Compounds]]